-
公开(公告)号：US5403825A
公开(公告)日：1995-04-04
申请号：US937744
申请日：1992-09-01
CPC分类号： C07K14/51 , A61K38/00 , Y10S530/84
摘要： Described is a purified osteogenic factor that when delivered to bone in association with a physiologically acceptable delivery vehicle is capable of inducing new bone growth at the bone surface. The osteogenic factor is water soluble, and is characterized physically by a molecular weight of about 2.5 kD when measured by gel filtration under dissociating conditions and an isoelectric point in the pH range from about 4.6 to 7.2. Use of the purified factor in treating bone defects is described. Also described is a method for obtaining the purified factor from mammalian bone.
摘要翻译： 描述了一种纯化的成骨因子，当与生理上可接受的递送载体相关联地递送至骨骼时，能够在骨表面诱导新的骨生长。 成骨因子是水溶性的，并且在离解条件下通过凝胶过滤测量时的分子量为约2.5kD的物理特征，以及在约4.6至7.2的pH范围内的等电点。 描述了纯化因子在治疗骨缺损中的用途。 还描述了从哺乳动物骨骼获得纯化因子的方法。
-
公开(公告)号：US5331094A
公开(公告)日：1994-07-19
申请号：US963246
申请日：1992-10-19
CPC分类号： C07K16/2869 , C07K14/71 , C07K16/4258 , A61K38/00 , A61K39/00
摘要： The invention relates to a purified somatostatin receptor which is purified at least about 30,000-fold over the receptor which is membrane-bound. The invention also provides pharmaceutical compositions containing the receptor and antibodies to the receptor.
摘要翻译： 本发明涉及一种纯化的生长抑素受体，该受体在被膜结合的受体上纯化至少约30,000倍。 本发明还提供含有该受体的药物组合物和该受体的抗体。
-
公开(公告)号：US5276138A
公开(公告)日：1994-01-04
申请号：US993522
申请日：1992-12-16
申请人： Masaru Yamada , Satoshi Narita , Takashi Kondo , Masaharu Nojima , Ryohei Yamamoto , Toyokazu Nishino , Chikaaki Sakai
发明人： Masaru Yamada , Satoshi Narita , Takashi Kondo , Masaharu Nojima , Ryohei Yamamoto , Toyokazu Nishino , Chikaaki Sakai
CPC分类号： A61Q19/00 , A61K8/985 , C07K14/47 , C08H1/06 , Y10S530/842
摘要： The present invention provides the process for treating the animal hairs by solubilization wherein the animal hairs can be treated in a short time without any complicated operations and special apparatuses, and the process for recovering the solubilized product of the animal hairs wherein said product can be recovered simply and efficiently from the solution thereof. The former is the process for treating animal hairs by solubilization which comprises solubilizing the animal hairs in a weak alkaline liquid medium in the presence of an oxidizing agent whose concentration is high. The latter is the process for recovering a solubilized product of animal hairs which comprises admixing a solution of said product with an organic acid or an aqueous solution thereof to precipitate said product.
摘要翻译： 本发明提供了通过溶解处理动物毛发的方法，其中动物毛发可以在短时间内进行处理而没有任何复杂的操作和特殊装置，以及回收动物毛的溶解产物的方法，其中所述产物可以回收 从其解决方案简单有效地进行。 前者是通过溶解处理动物毛发的过程，其包括在浓度高的氧化剂存在下将动物毛发溶解在弱碱性液体介质中。 后者是回收动物毛的溶解产物的方法，其包括将所述产物的溶液与有机酸或其水溶液混合以沉淀所述产物。
-
4.发明授权Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone 失效用于治疗和修复软骨或骨骼中缺陷或损伤的方法和组合物
公开(公告)号：US5270300A
公开(公告)日：1993-12-14
申请号：US756164
申请日：1991-09-06
申请人： Ernst B. Hunziker
发明人： Ernst B. Hunziker
IPC分类号： A61K38/00 , A61F2/00 , A61F2/02 , A61F2/28 , A61F2/30 , A61K31/727 , A61K38/17 , A61K38/18 , A61K38/22 , A61L24/00 , A61L24/10 , A61L27/00 , A61L27/22 , A61L27/54 , A61P19/04 , A61P43/00 , C12N15/06 , C07K15/06 , A61K37/22 , A61K37/24 , A61K37/36 , C09H3/02
CPC分类号： A61K38/1825 , A61F2/28 , A61F2/30756 , A61K38/1841 , A61L24/0015 , A61L24/106 , A61L27/227 , A61L27/54 , A61F2/2846 , A61F2002/2817 , A61F2002/30062 , A61F2002/30677 , A61F2210/0004 , A61F2310/00365 , A61L2300/254 , A61L2300/414 , A61L2300/45 , A61L2300/626 , A61L2430/02 , Y10S514/944 , Y10S514/965 , Y10S530/84
摘要： Methods and compositions are provided for the treatment and repair of defects in the cartilage or bone of humans and other animals as in full-thickness defects in joints. The defect in bone is filled with a matrix having pores large enough to allow cells to populate the matrix and to form blood vessels. The matrix filling the bone defect contains an angiogenic factor and also contains an osteogenic factor in an appropriate delivery system. To induce cartilage formation, a defect in cartilage is filled with a matrix having pores sufficiently large to allow cartilage repair cells to populate the matrix. The matrix filling the defect in cartilage contains a proliferation agent and also contains a transforming factor in an appropriate delivery system. The matrix may also contain a chemotactic agent to attract cartilage repair cells. In a full-thickness defect, the defect sites in bone and cartilage are separated from each other by a membrane, which is sealed to the cartilage-bone-junction and which prevents blood vessels and associated cells from penetrating from one site to the other.
-
公开(公告)号：US5264555A
公开(公告)日：1993-11-23
申请号：US913138
申请日：1992-07-14
申请人： Robert G. L. Shorr , Kwang Nho , Myung-ok P. Cho , Chyi Lee , Barbara Czuba , Hariharan Shankar
发明人： Robert G. L. Shorr , Kwang Nho , Myung-ok P. Cho , Chyi Lee , Barbara Czuba , Hariharan Shankar
IPC分类号： C07K14/805 , C07K3/02 , C07K3/12 , C07K3/22 , C07K15/06
CPC分类号： C07K14/805
摘要： Methods are disclosed for separating hemoglobin from erythrocytes by contacting erythrocytes with a hypotonic buffer solution at a rate sufficient to render the release of hemoglobin from said erythrocytes without significant lysis. The hemoglobin is then separated from the erythrocytes. Methods are also disclosed for purifying hemoglobin solutions of DNA, endotoxins and phospholipids by contacting the hemoglobin solutions with an anion exchange medium.
摘要翻译： 公开了通过使红细胞与低渗缓冲溶液接触的速率，以足以使血红蛋白从所述红细胞中释放而没有显着裂解的速率来分离血红蛋白与红细胞的方法。 然后将血红蛋白与红细胞分离。 还公开了通过使血红蛋白溶液与阴离子交换介质接触来纯化DNA，内毒素和磷脂的血红蛋白溶液的方法。
-
公开(公告)号：US5264209A
公开(公告)日：1993-11-23
申请号：US632070
申请日：1990-12-21
IPC分类号： A61K38/00 , A61P7/00 , C07K1/107 , C07K1/113 , C07K14/00 , C07K14/52 , C07K14/54 , C12N15/24 , C07K15/06 , A61K37/02
CPC分类号： C07K14/5412 , A61K38/00
摘要： Provided are PEGylated "interleukin-6" derivatives (PEG IL-6) having an extended plasma half-life, as well as enhanced in-vivo IL-6 biological activities.Methods for producing the modified glycosylated and unglycosylated IL-6 proteins or polypeptides, as well as, for their use in treating hematopoietic disorders and difficiencies, particularly acute thrombocytopenia, are also provided.
-
公开(公告)号：US5258497A
公开(公告)日：1993-11-02
申请号：US552172
申请日：1990-07-13
IPC分类号： C12P21/00 , C07K1/16 , C07K14/005 , C07K14/195 , C07K14/47 , C12R1/19 , C07K3/02 , C07K15/06 , C07K15/16
CPC分类号： C07K14/4721
摘要： The present invention relates to processes for purifying annexines. The overall process includes the steps of preparing a homogenized cell preparation and adjusting the pH to about 8.0 to 10.0, adding at least one bivalent cation, adding a phospholipid, washing the insoluble cell residue to remove the soluble constituents, and extracting the annexines from the cell residue with a chelating agent. This process initially promotes the adsorption of the annexines onto the insoluble cell residue or membrane of the host organism. The adsorption step makes it possible to eliminate unwanted soluble matter from the homogenized material by simple washing. Desorption is accomplished by using a chelating agent.
摘要翻译： 本发明涉及净化附睾的方法。 整个方法包括以下步骤：制备均匀的细胞制剂并将pH调节至约8.0至10.0，加入至少一种二价阳离子，加入磷脂，洗涤不溶性细胞残渣以除去可溶性成分，并从 细胞残留物与螯合剂。 该过程最初促进附着物吸附到宿主生物体的不溶性细胞残留物或膜上。 吸附步骤可以通过简单的洗涤从均质材料中除去不需要的可溶物质。 通过使用螯合剂来完成解吸。
-
公开(公告)号：US5252709A
公开(公告)日：1993-10-12
申请号：US460972
申请日：1990-04-06
IPC分类号： A61K38/16 , A61K35/16 , A61K38/43 , C07K1/18 , C07K14/435 , C07K14/745 , C07K14/755 , C07K14/78 , C07K3/22 , C07K15/06
CPC分类号： C07K14/755
摘要： The invention relates to a process for separating proteins from a fraction of human or animal plasma.According to this process, a solubilized fraction of cryoprecipitated plasma is subjected to a single stage of chromatography on a moderately ionic anion exchange resin permitting hydrophobic interactions to take place, which does not adsorb certain proteins and fixes others, which are then eluted by increasing the ionic strength of the buffer by the addition of NaCl.The process according to the invention makes it possible, in particular, to obtain a Factor VIII concentrate of high purity that can be used for the treatment of haemophilia A. The process also makes it possible to obtain concentrates of fibrinogen, Von Willebrand's factor and fibronectin.
摘要翻译： PCT No.PCT / FR89 / 00050 Sec。 371日期：1990年4月6日 102（e）日期1990年4月6日PCT提交1989年2月8日PCT公布。 出版物WO89 / 12065 日本1989年12月14日。本发明涉及从人或动物血浆部分中分离蛋白质的方法。 根据该方法，将冷沉淀的等离子体的溶解部分在中等离子阴离子交换树脂上进行单层色谱，允许发生疏水相互作用，其不吸附某些蛋白质并固定其它蛋白质，然后通过增加 通过加入NaCl的缓冲液的离子强度。 根据本发明的方法使得特别可以获得可用于治疗血友病A的高纯度因子VIII浓缩物。该方法还使得可以获得纤维蛋白原浓度，Von Willebrand因子和纤连蛋白 。
-
9.发明授权Novel method for disinfecting red blood cells, blood platelets, blood plasma, and optical corneas and sclerae 失效用于消毒红细胞，血小板，血浆和光学角膜和巩膜的新方法
公开(公告)号：US4971760A
公开(公告)日：1990-11-20
申请号：US230839
申请日：1988-08-09
申请人： Alan I. Rubinstein
发明人： Alan I. Rubinstein
CPC分类号： A61L2/0088 , A61K33/14 , A61K33/40 , Y10S514/833
摘要： It is well known that the transfusion of human blood and blood constituents, or the transplantation of corneas and sclerae, carries a substantial risk of transmission of AIDS and many other diseases. This disclosure describes a method of disinfecting certain blood constituents--particularly the red cells, platelets and proteins--or disinfecting corneal and scleral tissues, to make them safer for human transfusion or transplantation, while respectively maintaining their biologic or optical function. A sterilizing solution is prepared from, e.g., a commercially available disinfectant (such as LD.RTM. of Alcide Corporation) containing primarily lactic acid and sodium chlorite. Normal saline solution is used as diluent instead of distilled water. The blood constituent or cornea or sclera is exposed to the disinfectant for a time sufficient to inactivate or reduce the infectivity of disease agents. The normal-saline environment prevents or deters hemolysis of the red blood cells or damage to the corneal or scleral epithelium or endothelium, disruption of the platelets, or denaturation of the proteins. The blood cells or platelets (or both), or the cornea or sclera (or both) are then washed with normal saline solution until the disinfectant concentration is insignificant. Plasma proteins are precipitated out as with ammonium sulfate, resuspended and dialyzed to remove residual disinfectant and coagulant, and reconstituted. The blood constitutents or eye parts are then safe for human transfusion or transplantation.
摘要翻译： 众所周知，人血液和血液成分的输血，角膜和巩膜的移植具有传播艾滋病和许多其他疾病的重大风险。 本公开描述了一种消除某些血液成分（特别是红细胞，血小板和蛋白质）或消毒角膜和巩膜组织的方法，以使它们更安全地用于输血或移植，同时分别保持其生物学或光学功能。 由例如主要含有乳酸和亚氯酸钠的市售消毒剂（例如Alcide Corporation的LD TM）制备灭菌溶液。 使用生理盐水作为稀释剂而不是蒸馏水。 将血液成分或角膜或巩膜暴露于消毒剂足以灭活或降低疾病剂的感染性的时间。 正常盐水环境可防止或阻止红细胞溶血或损伤角膜或巩膜上皮或内皮，破坏血小板或蛋白质变性。 然后用生理盐水溶液洗涤血细胞或血小板（或两者）或角膜或巩膜（或两者）直到消毒剂浓度不显着。 血浆蛋白质与硫酸铵一样沉淀出来，重新悬浮并透析以除去残留的消毒剂和凝结剂，并重构。 血液成分或眼睛部分可以安全地用于输血或移植。
-
10.发明授权Regulatory glycoprotein for immune response and the use there of in the production of T-cell growth factor 失效用于免疫应答的调节糖蛋白及其在生产T细胞生长因子中的应用
公开(公告)号：US4661447A
公开(公告)日：1987-04-28
申请号：US514197
申请日：1983-07-15
CPC分类号： C07K14/55
摘要： A cell mediated immune response system glycoprotein having a molecular weight of about 90,000 and having at least one sialic acid moiety as a biologically active site is disclosed. The glycoprotein is specifically bound by wheat germ agglutinin and also by the hydrophobically binding ligand Blue A (Cibacron Blue F3G-A) but does not bind to lysine. The glycoprotein is a necessary cofactor with Interleukin-1 in the biosynthesis of T-cell growth factor (I1-2). A process for producing a serum-free and mitogen-free I1-2 in vitro by adding the glycoprotein to a serum-free- and mitogen-free Interleukin-1 preparation is described. The method for producing the serum-free and mitogen-free Interleukin-1 is also described. A chemically defined T-cell growth culture medium containing the new glycoprotein as the only protein substance is used in the above process and also provides a means for studying regulation of T-cell lymphocyte growth. Inhibitors for the formation of T-cell blasts in cell mediated immunological response provide a powerful new tool for preventing host-graft rejection. These inhibitors are alkylating agents for serine esterase enzymes which have been found to be involved in the cell mediated immunological response system which generates natural Killer (NK) cells, the latter being responsible for graft rejection in a host.
摘要翻译： 公开了具有约90,000分子量并具有至少一个唾液酸部分作为生物活性部位的细胞介导的免疫应答系统糖蛋白。 糖蛋白与小麦胚芽凝集素特异性结合，也可通过疏水结合配体蓝A（Cibacron Blue F3G-A）结合，但不结合赖氨酸。 糖蛋白是白细胞介素-1在T细胞生长因子生物合成中的必需辅因子（I1-2）。 描述了通过将糖蛋白加入到无血清和无丝分裂素的白介素-1制剂中来在体外产生无血清和无丝分裂素的I1-2的方法。 还描述了产生无血清和无丝分裂素的白细胞介素-1的方法。 在上述方法中使用含有新糖蛋白作为唯一蛋白质的化学定义的T细胞生长培养基，并且还提供研究T细胞淋巴细胞生长调节的方法。 在细胞介导的免疫应答中形成T细胞母细胞的抑制剂为预防宿主移植物排斥提供了强大的新工具。 这些抑制剂是已经被发现参与细胞介导的免疫应答系统的丝氨酸酯酶的烷化剂，其产生天然杀伤（NK）细胞，后者负责宿主中的移植排斥反应。
-
-
-
-
-
-
-
-
-
搜索结果
98 条记录 (耗时 0.025 秒)
